---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-044876"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T14:06:36.708105+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences Q4 net income $29.3M; cash $302M; obesity and AATD data expected in 2025

## Summary
- Q4 2024 revenue $83.7M (up from $29.1M YoY); net income $29.3M vs prior year net loss $16.3M.
- Full year 2024 net loss $97.0M, compared to $57.5M in 2023; R&D expenses increased to $159.7M.
- Cash $302.1M as of Dec 31, 2024, expected operating runway into 2027; excludes potential GSK milestones.
- Dosing underway in INLIGHT trial of WVE-007 in obesity; clinical data expected 2H 2025.
- On track to deliver FORWARD-53 48-week DMD data and FDA feedback on accelerated approval in 1Q 2025.

## SEC filing metadata
- accession: 0001193125-25-044876
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312525044876/0001193125-25-044876-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312525044876/d785711d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-044876
- JSON: https://secwatch.observer/filing/0001193125-25-044876.json
- Plain text: https://secwatch.observer/filing/0001193125-25-044876.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.